Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
The submission is backed by positive results from the Phase 3 AFFIRM study
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
nSEPIA aims to bring structure to an area long dominated by subjectivity
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
At IIT Roorkee’s Vision 2047 conference, the union minister highlights BioE3 policy, rising biotech startups, and major scientific milestones
AI-powered platform uses real-time emotion scanning and personalised interventions to make emotional wellness measurable and actionable
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Subscribe To Our Newsletter & Stay Updated
